BAY 41-8543

CAS No. 256498-66-5

BAY 41-8543( BAY 418543 )

Catalog No. M13773 CAS No. 256498-66-5

BAY 41-8543 is an NO-independent sGC (soluble guanylyl cyclase) stimulator, inhibits collagen-mediated aggregation in washed human platelets (IC50=90 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 30 In Stock
5MG 46 In Stock
10MG 73 In Stock
25MG 150 In Stock
50MG 235 In Stock
100MG 343 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BAY 41-8543
  • Note
    Research use only, not for human use.
  • Brief Description
    BAY 41-8543 is an NO-independent sGC (soluble guanylyl cyclase) stimulator, inhibits collagen-mediated aggregation in washed human platelets (IC50=90 nM).
  • Description
    BAY 41-8543 is an NO-independent sGC (soluble guanylyl cyclase) stimulator, inhibits collagen-mediated aggregation in washed human platelets (IC50=90 nM); BAY 418543 is a potent direct stimulator of the cyclic GMP/PKG/VASP pathway in platelets and synergizes with NO over a wide range of concentrations. Hypertension Discontinued.
  • In Vitro
    ——
  • In Vivo
    BAY 41-8543 (10-100 μg/kg; IV) produces small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output.BAY 41-8543 (0.003, 0.01, 0.03, 0.1, and 0.3?mg/kg; iv) produces a dose-dependent and long-lasting decrease in blood pressure in anaesthetized rats. The blood pressure lowering effect of BAY 41-8543 lasts longer than the observation period of 30?min. BAY 41-8543 (0.1, 0.3 and 1.0?mg?kg; oral) has maximal blood pressure lowering effects. The blood pressure lowering effects of the highest doses of BAY41-8543 lasts longer than the observation period of 120?min. BAY 41-8543 (3?mg/kg; p.o.; twice daily; for 5 weeks) completely prevents the development of the increase in systolic blood pressure in 18-week-old renin transgenic rats (TGR(mRen2)27) on L-NAME treatment. BAY 41-8543 dramatically increases survival. Animal Model:Adult male Sprague-Dawley rats weighing 325-450 g Dosage:10, 30, and 100 μg/kg Administration:IV Result:Produced small decreases in pulmonary arterial pressure, larger dose-dependent decreases in systemic arterial pressure, and increases in cardiac output.
  • Synonyms
    BAY 418543
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Guanylate Cyclase
  • Recptor
    Guanylate Cyclase
  • Research Area
    Cardiovascular Disease
  • Indication
    Hypertension

Chemical Information

  • CAS Number
    256498-66-5
  • Formula Weight
    420.452
  • Molecular Formula
    C21H21FN8O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMF : 16.67 mg/mL (39.65 mM)
  • SMILES
    c1ccc(c(c1)Cn2c3c(cccn3)c(n2)c4nc(c(c(n4)N)N5CCOCC5)N)F
  • Chemical Name
    2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-4,6-pyrimidinediamine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Stasch JP, et al. Br J Pharmacol. 2002 Jan;135(2):333-43. 2. Stasch JP, et al. Br J Pharmacol. 2002 Jan;135(2):344-55. 3. Amirjanians M, et al. Oncotarget. 2017 May 2;8(18):29613-29624.
molnova catalog
related products
  • BAY 41-2272

    BAY 41-2272 is a potent, NO-independent, orally available soluble guanylate cyclase (sGC) stimulator with IC50 of 0.3 uM.

  • Plecanatide

    Plecanatide acetate is an analogue of Uroguanylin. It is an orally active guanylate cyclase-C (GC-C) receptor agonist.

  • Linaclotide

    A potent and selective GC-C agonist (Ki=1.23-1.64 nM) that elicits pharmacological effects locally in the gastrointestinal tract.